Health Care & Life Sciences » Biotechnology | Idera Pharmaceuticals Inc.

Idera Pharmaceuticals Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
18,226.00
38,642.00
48,555.00
38,389.00
65,984.00
59,881
Depreciation, Depletion & Amortization
137.00
206.00
488.00
656.00
746.00
432
Other Funds
1,554.00
4,642.00
6,306.00
7,589.00
10,964.00
6,248
Funds from Operations
16,535.00
33,794.00
41,761.00
30,144.00
54,274.00
53,201
Changes in Working Capital
602.00
2,473.00
1,225.00
1,941.00
985.00
1,285
Net Operating Cash Flow
17,137.00
31,321.00
42,986.00
28,203.00
55,259.00
51,916
Capital Expenditures
9.00
1,093.00
727.00
408.00
206.00
Purchase/Sale of Investments
9,331.00
19,508.00
32,687.00
31,774.00
28,270.00
Net Investing Cash Flow
9,340.00
20,601.00
33,414.00
31,366.00
28,064.00
Cash Dividends Paid - Total
1,066.00
798.00
-
-
-
Issuance/Reduction of Debt, Net
4.00
5.00
130.00
268.00
303.00
Net Financing Cash Flow
42,659.00
45,615.00
83,015.00
50,918.00
59,157.00
Net Change in Cash
16,182.00
6,307.00
6,615.00
54,081.00
31,962.00
Free Cash Flow
17,146.00
32,414.00
43,713.00
28,611.00
55,465.00
Change in Capital Stock
43,729.00
46,418.00
83,145.00
51,186.00
59,460.00

About Idera Pharmaceuticals

View Profile
Address
505 Eagleview Boulevard
Exton Pennsylvania 19341
United States
Employees -
Website http://www.iderapharma.com
Updated 07/08/2019
Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which focuses on the discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases. The firm uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates: Toll-like receptor targeting technology and third-generation antisense technology. The company was founded by Paul C.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.